|Articles|June 26, 2011

Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.

Stay informed with the Medical Economics eNewsletter, delivering expert insights, financial strategies, practice management tips, and technology trends tailored for today’s physicians.

Latest CME

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Medical Economics

How AI, online reviews and rising standards are redrawing the path to care

Nearly half of internal medicine's workforce was born abroad, new JAMA study finds

Why physicians can't collect Medicare Advantage copays like they used to

What primary care physicians need to know about Trump’s vaccine order

CMS is asking what RPM devices cost. Physicians must answer.